Doxercalciferol vs Paricalcitol — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Vitamin D2 Analog

Doxercalciferol

First FDA approval: 2019-09-26

Vitamin D2 Analog

Paricalcitol

Brand: Zemplar

First FDA approval: 1998-04-17

Lowest NADACAcquisition cost floor across all NDCs

—Per unit

$1.06Per unit

Average NADACAcross all dosage forms and strengths

—

$1.46Up to $1.86

Generic manufacturersActive ANDA holders — FDA Orange Book

913 total ANDAs filed

1032 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$902583Full year

$4.5MFull year

Part D claims (CY24)Total fills, all strengths

2K580 beneficiaries

42K12K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$470Per claim, all NDCs

$106Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

93Minimal friction

252Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

9Limited friction

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

DiscontinuedSee drug profile

Generic availableFDA Orange Book

Yes9 manufacturers

Yes10 manufacturers